rd06-05
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 15, 2025 (NCT06775912)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Anti-Glomerular Basement Membrane Disease · Early Phase 1
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Early Phase 1
- Glomerulonephritis · Early Phase 1
- Lupus Erythematosus, Systemic · Early Phase 1
- Multiple Sclerosis · Early Phase 1
- Myositis · Early Phase 1
- Neuromyelitis Optica · Early Phase 1
- Scleroderma, Systemic · Early Phase 1
- Sclerosis · Early Phase 1
- Vasculitis · Early Phase 1
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07309744 | Early Phase 1 (Phase 1) | Dec 20, 2025 | Huazhong University of Science and Technology |
| NCT07203404 | Early Phase 1 (Phase 1) | Jul 24, 2025 | Nanjing Bioheng Biotech Co., Ltd. |
| NCT06775912 | Early Phase 1 (Phase 1) | Jan 15, 2025 | Nanjing Bioheng Biotech Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nanjing Bioheng Biotech Co., Ltd. | For profit | 2 | 2 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1